Invasive fungal infections remain a major cause of morbidity and mortality, particularly in immunocompromised patients. 1 The majority of fungal infections are caused by Candida or Aspergillus sp. Recently, the spectrum of fungal infections has significantly changed in favour of non-Candida albicans species, such as C. tropicalis, C. krusei, C. guillermondii, C. dubliniensis and C. glabrata. 2 In addition, the emergence of azole resistance (mainly to fluconazole) 3 and toxicity have resulted in the need for an expanded arsenal of antifungal drugs, such as Caspofungin. 4 We report a patient with acute myeloid leukemia (AML) in CR, undergoing unrelated allogeneic hematopoietic stem cell transplant (HSCT), who developed a C. krusei fungemia, successfully treated with Caspofungin.
A 34-year-old man was diagnosed as AML FAB M5a, CD34 þ , normal karyotype and FLT3 ITD þ . He underwent a peripheral HSCT from an unrelated donor as he lacked an HLA-identical sibling. Antibacterial and antifungal prophylaxis consisted of oral ciprofloxacin (500 mg/ day) and oral itraconazole (200 mg/day, started on day À7). Surveillance cultures from the nose, throat, axilla, perineum, rectum and stool were taken weekly.
CMV prophylaxis was with ganciclovir 10 mg/kg from day À7 to À2 and Foscarnet 90 mg/kg from day þ 4 to þ 20. Complete engraftment was on day þ 18. On day þ 38, a febrile episode occurred (39.51C) while the patient was still leucopenic (WBC 2.8 Â 10 9 /l, with neutrophil 41000/mmc). All blood cultures (from CVC and from peripheral vein) were positive for Escherichia coli and chest X-ray revealed pulmonary infiltrates; expectorated sputum also grew E. coli. The patient was given imipenem (1 g/ t.i.d.) plus vancomycin (2g/day). However, fever did not diminish and further blood cultures were taken. On day 6 of persistent fever, blood cultures (one from CVC and three from peripheral vein) were positive for C. krusei. Fungal identification and susceptibility tests were obtained according to standard microbiological techniques (AMS Vitek 2, USA and Yeast One System, Biomedical). In vitro susceptibility tests indicated sensitivity to amphotericin B (MIC 1 mg/ml), to 5-flucytosine (MIC 4), intermediate sensitivity to voriconazole (MIC 1), and resistance to fluconazole and itraconazole (MIC 64), according to NCCLS M27-A2 for 5-flucytosine, fluconazole and itraconazole. Surveillance cultures were persistently negative for fungi.
It was not possible to remove the central venous catheter due to difficult vascular access and liposomal amphoterin B (3 mg/kg/day) was added. During antifungal treatment the previous pulmonary infiltrates resolved (documented by chest X-ray and by computed tomography), but fever continued to spike (391C). Blood cultures, taken on days 7 and 14 after institution of Ambisome, continued to be positive for Candida krusei (two from peripheral vein) and Ambisome was discontinued on day 15. During this period, no evidence of renal failure or any organ involvement was documented. On the basis of susceptibility tests (resistance to fluconazole and itraconazole, intermediate sensitivity to voriconazole), therapy with Caspofungin was started (70 mg intravenous loading dose followed by daily i.v. therapy of 50 mg given over 1 h). No dosage adjustment was necessary for renal failure. The patient became afebrile 5 days after the institution of Caspofungin acetate; control blood cultures, taken on day 5, were negative. The patient continued to receive the Caspofungin acetate therapy along with imipenem/cilastatin and vancomycin. Therapy with Caspofungin was completed after a 2-week course with no toxicity.
C. krusei has emerged as an important and still unfavorable pathogen, causing fungemia in immunocompromised patients. As C. krusei is considered resistant to fluconazole, the armamentarium is limited to Amphotericin B and, more recently, to new drugs such as voriconazole and the echinocandins. 4 Echinocandins, such as Caspofungin acetate, are a new class of antifungal agents associated with minimal toxicity, which inhibit the synthesis of 1,3-b-D-glucan, a key step in fungal cell wall biosynthesis. 5 Thus, having a different mode of action, they may constitute effective therapeutic options for the management of a variety of fungal infections, including those that are refractory to azoles or to amphotericin B. 6 In our patient with C. krusei fungemia, therapy with liposomal amphotericin B failed, despite in vitro sensitivity, and recovery occurred only after Caspofungin treatment, as also reported in a patient with acute lymphoblastic leukemia; 7 this report seems to be the first case in a patient undergoing stem cell transplantation.
In conclusion, Caspofungin is an alternative and promising agent for refractory C. krusei fungemia in the setting of severe immunocompromise such as after allogeneic HSCT. 
